文献速递关节外科

脂质体布比卡因局部浸润镇痛改善全膝关节置换术后早期结局:PILLAR研究24小时数据

Local Infiltration Analgesia With Liposomal Bupivacaine Improves Early Outcomes After Total Knee Arthroplasty: 24-Hour Data From the PILLAR Study.
PubMed 文献 · J Arthroplasty · 2018-12-25

PILLAR研究将膝骨关节炎患者随机分组,比较脂质体布比卡因266 mg联合布比卡因盐酸盐与单用布比卡因盐酸盐局部浸润镇痛在全膝关节置换术后0-24小时的效果。结果显示联合组阿片类药物需求、疼痛强度显著降低,出院准备度和满意度显著提高,不良事件发生率相似。

要点

  • 脂质体布比卡因联合布比卡因盐酸盐局部浸润镇痛较单用布比卡因盐酸盐显著降低术后24小时内阿片类药物消耗和疼痛强度。
  • 联合组出院准备度42.9% vs 27.5%(P = .0449),疼痛治疗满意度84.6% vs 69.2%(P = .0306)。
  • 两组不良事件发生率相似,联合组需要阿片类药物补救的相对风险为0.085(95%CI 0.011-0.633)。

核心结论

  • 与单用布比卡因盐酸盐相比,脂质体布比卡因266 mg联合布比卡因盐酸盐局部浸润镇痛显著降低全膝关节置换术后0-24小时阿片类药物需求和疼痛强度,并显著改善出院准备度和满意度。
  • 这些发现支持在以早期出院为目标的全膝关节置换术中采用脂质体布比卡因局部浸润镇痛。

研究设计与样本

  • PILLAR研究是一项随机、1:1分组的研究,纳入膝骨关节炎患者,比较脂质体布比卡因266 mg/20 mL混合布比卡因盐酸盐0.5% 20 mL局部浸润镇痛(n=70)与单用布比卡因盐酸盐局部浸润镇痛(n=69)。
  • 本报告为PILLAR研究预设的次要和三级终点,分析全膝关节置换术后24小时内的结局,并评估安全性。

主要发现

  • 脂质体布比卡因组术后24小时内需要阿片类药物补救的可能性降低16%(17.1% vs 1.4%;相对风险0.085;95%CI 0.011-0.633)。
  • 脂质体布比卡因组阿片类药物消耗量降低91%(P = .0009),疼痛强度降低19%(P = .0142)。
  • 脂质体布比卡因组出院准备度显著更高(42.9% vs 27.5%;P = .0449),疼痛治疗满意度显著更高(84.6% vs 69.2%;P = .0306)。
  • 达到步态稳定/无头晕的比例在脂质体布比卡因组数值上更低但无显著差异(42.9% vs 52.2%)。
  • 两组不良事件发生率相似。

关键数值与推荐

  • 脂质体布比卡因266 mg/20 mL混合布比卡因盐酸盐0.5% 20 mL局部浸润镇痛组需要阿片类药物补救的比例为17.1%,单用布比卡因盐酸盐组为1.4%(相对风险0.085;95%CI 0.011-0.633)。
  • 脂质体布比卡因组阿片类药物消耗量降低91%(P = .0009),疼痛强度降低19%(P = .0142)。
  • 脂质体布比卡因组出院准备度为42.9%,单用布比卡因盐酸盐组为27.5%(P = .0449)。
  • 脂质体布比卡因组疼痛治疗满意度为84.6%,单用布比卡因盐酸盐组为69.2%(P = .0306)。
  • 达到步态稳定/无头晕的比例在脂质体布比卡因组为42.9%,单用布比卡因盐酸盐组为52.2%,无显著差异。

临床怎么用

  • 原文结论指出,这些发现支持在以早期出院为目标的全膝关节置换术中采用脂质体布比卡因局部浸润镇痛。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced postoperative care pathways have shifted total knee arthroplasty (TKA) to outpatient and short-stay settings, placing greater emphasis on predischarge outcomes. In this study, we report prespecified secondary and tertiary end points of the PILLAR study within 24 hours after TKA in patients receiving local infiltration analgesia (LIA) with or without liposomal bupivacaine (LB). METHODS: Patients with knee osteoarthritis were randomized 1:1 to receive LIA with LB 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL (n = 70) or bupivacaine HCl alone (n = 69). End points (0-24 hours postsurgery) were proportion of opioid-free patients, opioid consumption, areas under the curve of visual analog scale pain intensity scores, patient satisfaction, discharge readiness, and ambulation. Safety was also assessed. RESULTS: Patients receiving LIA with LB were 16% less likely to require opioid rescue within 24 hours postsurgery (17.1% vs 1.4%; relative risk, 0.085; 95% confidence interval, 0.011-0.633). LIA with LB was associated with a 91% reduction in opioid consumption (P = .0009) and 19% reduction in pain intensity (P = .0142). Significantly more patients receiving LB were discharge ready (42.9% vs 27.5%; P = .0449) and satisfied with pain treatment (84.6% vs 69.2%; P = .0306). A numerically lower but not significantly different proportion achieved steady gait/no dizziness with LIA with LB (42.9% vs 52.2%). Adverse event incidence was similar between groups. CONCLUSION: LIA with LB 266 mg plus bupivacaine HCl significantly reduced opioid requirements and pain intensity and significantly improved discharge readiness and satisfaction 0-24 hours after TKA compared with bupivacaine HCl alone. These findings support the use of LIA with LB for TKA when early discharge is the goal.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Dysart SH, Barrington JW, Del Gaizo DJ, et al. Local Infiltration Analgesia With Liposomal Bupivacaine Improves Early Outcomes After Total Knee Arthroplasty: 24-Hour Data From the PILLAR Study. J Arthroplasty. 2018. PMID: 30799269. doi:10.1016/j.arth.2018.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。